Effect of low (5 mg) vs. high (20-40 mg) rosuvastatin dose on 24h arterial stiffness, central haemodynamics, and non-alcoholic fatty liver disease in patients with optimally controlled arterial hypertension

Current Vascular Pharmacology

Volumn 16, Issue 4, 2018, Pages 393-400

  Mitsiou, Eudoxia ^a   Boutari, Chrysoula ^a   Kotsis, Vasilios ^a   Georgianou, Eleni ^a   Doumas, Michael ^a,b   Karagiannis, Asterios ^a   Athyros, Vasilios G ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Arterial hypertension; Arterial stiffness; Atheromatic plaque; Cardiovascular disease; Non alcoholic fatty liver disease; Rosuvastatin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CHOLESTEROL; CREATINE KINASE; CREATININE; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTERIAL STIFFNESS; ARTICLE; ATHEROSCLEROSIS; AUGMENTATION INDEX; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE COMPARISON; DRUG MEGADOSE; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; FEMALE; HEART FAILURE; HEART HEMODYNAMICS; HEART RATE; HUMAN; HYPERTENSION; LOW DRUG DOSE; MALE; MIDDLE AGED; MORTALITY; NONALCOHOLIC FATTY LIVER; PREVALENCE; PROSPECTIVE STUDY; PULSE PRESSURE; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; ARTERIAL PRESSURE; COMPARATIVE STUDY; COMPLICATION; DRUG EFFECT; GREECE; PATHOPHYSIOLOGY; RISK REDUCTION; TIME FACTOR; TREATMENT OUTCOME;

ADULT; ANTIHYPERTENSIVE AGENTS; ARTERIAL PRESSURE; FEMALE; GREECE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROSPECTIVE STUDIES; RISK FACTORS; RISK REDUCTION BEHAVIOR; ROSUVASTATIN CALCIUM; TIME FACTORS; TREATMENT OUTCOME; VASCULAR STIFFNESS;

EID: 85043978391     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161115666170630122833     Document Type: Article

References (67)

1. Townsend RR. Arterial stiffness: Recommendations and standardization. Pulse (Basel) 2017; 4(Suppl 1): 3-7.
2. Townsend RR, Wilkinson IB, Schiffrin EL, et al. Recommendations for improving and standardizing vascular research on arterial stiffness: A scientific statement from the American heart association. Hypertension 2015; 66: 698-722.
3. Hom EK, Duprez DA, Jacobs DR Jr, et al. Comparing arterial function parameters for the prediction of coronary heart disease events: The Multi-Ethnic Study of Atherosclerosis (MESA). Am J Epidemiol 2016; 184: 894-901.
4. Wu CF, Liu PY, Wu TJ, et al. Therapeutic modification of arterial stiffness: An update and comprehensive review. World J Cardiol 2015; 7: 742-53.
5. Ghosh RK, Bandyopadhyay D, Hajra A, et al. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies. Int J Cardiol 2016; 212: 29-36.
6. Tousoulis D, Oikonomou E, Siasos G, et al. Dose-dependent effects of short term atorvastatin treatment on arterial wall properties and on indices of left ventricular remodeling in ischemic heart failure. Atherosclerosis 2013; 227: 367-72.
7. Keating GM, Robinson DM. Rosuvastatin: A review of its effect on atherosclerosis. Am J Cardiovasc Drugs 2008; 8: 127-46.
8. Upala S, Wirunsawanya K, Jaruvongvanich V, et al. Effects of statin therapy on arterial stiffness: A systematic review and meta-analysis of randomized controlled trial. Int J Cardiol 2017; 227: 338-41.
9. Shimizu M, Kario K. Role of the augmentation index in hypertension. Ther Adv Cardiovasc Dis 2008; 2: 25-35.
10. Van Bortel LM, Laurent S, Boutouyrie P, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens 2012; 30: 445-8.
11. Vlachopoulos C, Aznaouridis K, Stefanadis C. Aortic stiffness for cardiovascular risk prediction: Just measure it, just do it. J Am Coll Cardiol 2014; 63: 647-9.
12. Reference Values for Arterial Stiffness' Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: Establishing normal and reference values. Eur Heart J 2010; 31: 2338-50.
13. Kotsis V, Antza C, Doundoulakis I, et al. Markers of early vascular ageing. Curr Pharm Des 2017; 23(22): 3200-04.
14. Chirinos JA, Kips JG, Roman MJ, et al. Ethnic differences in arterial wave reflections and normative equations for augmentation index. Hypertension 2011; 57: 1108-16.
15. Baulmann J, Homsi R, Uen S, et al. Pulse wave velocity is increased in patients with transient myocardial ischemia. J Hypertens 2006; 24: 2085-90.
16. Heffernan KS, Jae SY, Wilund KR, et al. Racial differences in central blood pressure and vascular function in young men. Am J Physiol Heart Circ Physiol 2008; 295: 2380-7.
17. Franssen PM, Imholz BP. Evaluation of the Mobil-O-Graph new generation ABPM device using the ESH criteria. Blood Press Monit 2010; 15: 229-31.
18. Wei W, Tölle M, Zidek W, et al. Validation of the mobil-O-Graph: 24 h-blood pressure measurement device. Blood Press Monit 2010; 15: 225-8.
19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
20. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-50.
21. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-818.
22. Wilkinson IB, MacCallum H, Flint L, et al. The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol 2000; 525: 263-70.
23. Kiuchi S, Hisatake S, Kawasaki M, et al. Addition of a renin-angiotensin-aldosterone system inhibitor to a calcium channel blocker ameliorates arterial stiffness. Clin Pharmacol 2015; 7: 97-102.
24. Wang F, Ye P, Luo L, et al. Association of serum lipids with arterial stiffness in a population-based study in Beijing. Eur J Clin Invest 2011; 41: 929-36.
25. Matsuo T, Iwade K, Hirata N, et al. Improvement of arterial stiffness by the antioxidant and anti-inflammatory effects of short-term statin therapy in patients with hypercholesterolemia. Heart Vessels 2005; 20: 8-12.
26. Liu B, Che W, Yan H, Zhu W, et al. Effects of rosuvastatin vs. simvastatin/ezetimibe on arterial wall stiffness in patients with coronary artery disease. Intern Med 2013; 52: 2715-9.
27. Liu B, Zhang JY, Cao HM, et al. Effect of rosuvastatin on ROCK activity, endothelial function, and inflammation in Asian patients with atherosclerosis. Intern Med 2012; 51: 1177-82.
28. Ishibashi Y, Matsui T, Takeuchi M, et al. Rosuvastatin blocks advanced glycation end products-elicited reduction of macrophage cholesterol efflux by suppressing NADPH oxidase activity via inhibition of geranylgeranylation of Rac-1. Horm Metab Res 2011; 43: 619-24.
29. Pei Y, Ma P, Wang X, et al. Rosuvastatin attenuates monocro-taline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism. Eur J Pharmacol 2011; 666: 165-72.
30. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The AS-TEROID trial. JAMA 2006; 295: 1556-65.
31. Nicholls SJ. Rosuvastatin and progression of atherosclerosis. Expert Rev Cardiovasc Ther 2008; 6: 925-33.
32. Zhang J, Zhou HJ, Ji W, et al. AIP1-mediated stress signaling in atherosclerosis and arteriosclerosis. Curr Atheroscler Rep 2015; 17: 503-9.
33. Cernes R, Zimlichman R, Shargorodsky M. Arterial elasticity in cardiovascular disease: Focus on hypertension, metabolic syndrome and diabetes. Adv Cardiol 2008; 45: 65-81.
34. Tissier F, Mallem Y, Goanvec C, et al. A non-hypocholesterolemic atorvastatin treatment improves vessel elasticity by acting on elastin composition in WHHL rabbits. Atherosclerosis 2016; 251: 70-7.
35. Briones AM, Rodríguez-Criado N, HernanzR, et al. Atorvastatin prevents angiotensin ii–induced vascular remodeling and oxidative stress. Hypertension 2009; 54: 142-9.
36. Chung JW, Lee YS, Kim JH, et al. Reference values for the augmentation index and pulse pressure in apparently healthy Korean subjects. Korean Circ J 2010; 40: 165-71.
37. Tziomalos K, Athyros VG, Karagiannis A. Treating arterial stiffness in young and elderly patients with the metabolic syndrome. Curr Pharm Des 2014; 20: 6106-13.
38. Katsiki N, Koumaras C, Athyros VG, et al. Thinking beyond traditional cardiovascular risk factors: The role of arterial stiffness in targeting residual risk. Angiology 2012; 63: 9-11.
39. Serban C, Sahebkar A, Ursoniu S, et al. A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. Sci Rep 2015; 5: 9902.
40. Ott C, Schneider MP, Schlaich MP, et al. Rosuvastatin improves pulse wave reflection by restoring endothelial function. Microvasc Res 2012; 84: 60-4.
41. Tziomalos K, Athyros VG, Karagiannis A, et al. Lipid lowering agents and the endothelium: An update after 4 years. Curr Vasc Pharmacol 2012; 10: 33-41.
42. Kanaki AI, Sarafidis PA, Georgianos PI, et al. Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia. Am J Hypertens 2013; 26: 608-16.
43. Tziomalos K, Karagiannis A, Athyros VG. Effects of lipid-lowering agents on inflammation, haemostasis and blood pressure. Curr Pharm Des 2014; 20: 6306-13.
44. Sarkar K, Sinha AK, Mehta JL. The role of statins in endothelial dysfunction in hypertension. Curr Opin Cardiol 2006; 21: 316-21.
45. Sahebkar A, Pećin I, Tedeschi-Reiner E. Effects of statin therapy on augmentation index as a measure of arterial stiffness: A systematic review and meta-analysis. Int J Cardiol 2016; 212: 160-8.
46. Athyros VG, Pagourelias ED, Gossios TD, et al. Treating heart failure with preserved ejection fraction related to arterial stiffness. can we kill two birds with one stone? Curr Vasc Pharmacol 2015; 13: 368-80.
47. Koh KK, Sakuma I, Hayashi T, et al. Renin-angiotensin system inhibitor and statins combination therapeutics-what have we learnt? Expert Opin Pharmacother 2015; 16: 949-53.
48. Athyros VG, Katsiki N, Karagiannis A, et al. Combination of statin plus renin angiotensin system inhibition for the prevention or the treatment of atherosclerotic cardiovascular disease. Curr Pharmaceutical Design 2014; 20:6299-305.
49. Athyros VG, Katsiki N, Karagiannis A. Is targeting microRNA the philosopher's stone for vascular disease? Curr Vasc Pharmacol 2016; 14: 88-97.
50. Lee HY, Sakuma I, Ihm SH, et al. Statins and renin-angiotensin system inhibitor combination treatment to prevent cardiovascular disease. Circ J 2014; 78: 281-7.
51. Koh KK, Han SH, Oh PC, et al. Combination therapy for treatment or prevention of atherosclerosis: Focus on the lipid-RAAS interaction. Atherosclerosis 2010; 209: 307-13.
52. Mose FH, Larsen T, Bech JN, et al. Effects of atorvastatin on systemic and renal nitric oxide in healthy man. Clin Exp Hypertens 2013; 35: 148-57.
53. Wagenaar LJ, Buikema H, Pinto YM, et al. Improvement of endothelial dysfunction in experimental heart failure by chronic RAAS-blockade: ACE-inhibition or AT1-receptor blockade? J Renin Angiotensin Aldosterone Syst 2001; 2(Suppl 1): 64-9.
54. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213-25.
55. Ferrier KE, Muhlmann MH, Baguet JP, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002; 39: 1020-5.
56. Han SH, Kang EW, Yoon SJ, et al. Combined vascular effects of HMG-CoA reductase inhibitor and angiotensin receptor blocker in non-diabetic patients undergoing peritoneal dialysis. Nephrol Dial Transplant 2011; 26: 3722-8.
57. Williams B, Lacy PS, Cruickshank JK, et al. Impact of statin therapy on central aortic pressures and hemodynamics: Principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study. Circulation 2009; 119: 53-61.
58. Manisty C, Mayet J, Tapp RJ, et al. Atorvastatin treatment is associated with less augmentation of the carotid pressure waveform in hypertension: A substudy of the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT). Hypertension 2009; 54: 1009-13.
59. Vlachopoulos C, Xaplanteris P, Aboyans V, et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European society of cardiology working group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) society. Atherosclerosis 2015; 241: 507-32.
60. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: A post-hoc analysis. Lancet 2010; 376: 1916-22.
61. Athyros VG, Tziomalos K, Katsiki N, et al. Cardiovascular risk across the histological spectrum and the clinical manifestations of non alcoholic fatty liver disease: An update. World J Gastroenterol 2015; 21: 6820-34.
62. Tikkanen MJ, Fayyad R, Faergeman O, et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 2013; 168: 3846-52.
63. Athyros VG, Giouleme O, Ganotakis ES, et al. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: A post hoc analysis of the randomised ATTEMPT study. Arch Med Sci 2011; 7: 796-805.
64. Kargiotis K, Athyros VG, Giouleme O, et al. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol 2015; 21: 7860-8.
65. Dongiovanni P, Petta S, Mannisto V, et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol 2015; 63: 705-12.
66. Nascimbeni F, Aron-Wisnewsky J, Pais R, et al. Statins, antidiabetic medications and liver histology in 95 patients with diabetes with non alcoholic fatty liver disease. BMJ Open Gastroenterol 2016; 3: e000075.
67. Athyros VG, Alexandrides TK, Bilianou H, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An expert panel statement. Metabolism 2017; 71: 17-32.